Valence8 US LP Invests $999,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Valence8 US LP bought a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 8,969 shares of the specialty pharmaceutical company’s stock, valued at approximately $999,000. Jazz Pharmaceuticals makes up approximately 0.4% of Valence8 US LP’s portfolio, making the stock its 13th largest holding.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Jazz Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock valued at $776,551,000 after buying an additional 84,941 shares in the last quarter. Covestor Ltd increased its position in Jazz Pharmaceuticals by 107.4% during the 1st quarter. Covestor Ltd now owns 618 shares of the specialty pharmaceutical company’s stock valued at $74,000 after buying an additional 320 shares in the last quarter. Advisors Asset Management Inc. boosted its stake in Jazz Pharmaceuticals by 9.2% during the 1st quarter. Advisors Asset Management Inc. now owns 9,722 shares of the specialty pharmaceutical company’s stock valued at $1,171,000 after purchasing an additional 819 shares during the last quarter. Capital World Investors purchased a new stake in Jazz Pharmaceuticals during the 1st quarter valued at $171,943,000. Finally, Estuary Capital Management LP boosted its stake in Jazz Pharmaceuticals by 67.2% during the 1st quarter. Estuary Capital Management LP now owns 213,450 shares of the specialty pharmaceutical company’s stock valued at $25,704,000 after purchasing an additional 85,779 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling

In related news, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the sale, the chief executive officer now owns 428,976 shares in the company, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,110 shares of company stock worth $720,160. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $125.10 on Friday. The firm has a market cap of $7.56 billion, a price-to-earnings ratio of 17.62, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The business has a 50-day moving average price of $112.92 and a 200-day moving average price of $110.52. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17.

Analysts Set New Price Targets

Several brokerages have commented on JAZZ. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. increased their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Wells Fargo & Company cut their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Finally, TD Cowen dropped their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $175.33.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.